• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
HUANG Juan,ZHANG Miling,YU Junhe,GONG Shuaishuai,KOU Junping.Research progress on the mechanism of hemorrhagic transformation caused by tPA thrombolysis and the intervention effect of small molecule compounds[J].Journal Of Pharmaceutical Research,2024,43(4):384-390,401[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2663times   Download 2880次 QR Code for this article
Scan with your phone!
tPA溶栓引起的出血性转化机制及小分子化合物干预作用研究进展
黄娟,张米玲,余俊河,宫帅帅,寇俊萍
Font:Larger+|Default|Smaller-
(中国药科大学中药学院中药药理与中医药系,江苏 南京 211198)
摘要:
组织型纤溶酶原激活剂(Tissue type plasmin activator ,tPA)是美国食品药品监督管理局唯一批准的用于急性缺血性卒中治疗的药物,但由于治疗时间窗狭窄以及会导致严重的出血转化(Hemorrhagic transformation,HT),其临床应用受到限制。本文拟从血脑屏障破坏、神经炎症、氧化应激以及亚硝酸应激等方面对HT发展的机制及近7年来发表在国内外期刊上的小分子化合物对HT保护的研究进展予以综述,为缺血性中风的新药开发和药物联用提供一定参考。
关键词:  组织型纤溶酶原激动剂  出血性转化  小分子化合物  研究进展
DOI:10.13506/j.cnki.jpr.2024.04.013
基金项目:江苏省自然科学基金(No.SBK20210432)
Publication Date:April 25, 2024
Research progress on the mechanism of hemorrhagic transformation caused by tPA thrombolysis and the intervention effect of small molecule compounds
HUANG Juan,ZHANG Miling,YU Junhe,GONG Shuaishuai,KOU Junping
(Department of Pharmacology of Chinese Materia Medica, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China)
Abstract:
Tissue type plasmin activator (tPA) is the only drug approved by the US Food and Drug Administration for the treatment of acute ischemic stroke. However, its clinical application is limited due to the narrow treatment time window and severe hemorrhagic transformation (HT). In this paper, the mechanism of HT development was reviewed from the perspectives of blood-brain barrier disruption, neuroinflammation, oxidative stress, and nitrite stress, as well as the research progress of small molecule compounds on HT protection published in domestic and foreign journals in the past seven years. This information would provide some clues and references for the new drug development and drug combination for the ischemic stroke.
Key words:  Tissue plasmin activator  Hemorrhagic transformation  Small molecule compounds  Research progress
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.